Mersana Therapeutics reports positive phase 1 data for novel ADC in triple-negative breast cancer
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical innovator, has announced promising early clinical data from its Phase 1 trial evaluating emiltatug ledadotin (Emi-Le; XMT-1660), an antibody-drug ... Read More
Innovent Biologics and Roche partner to advance DLL3 antibody drug conjugate
Innovent Biologics, Inc., a biopharmaceutical company, has entered a strategic global licensing agreement with Roche to propel the development of IBI3009, a novel DLL3-targeted antibody-drug ... Read More
Suven Pharmaceuticals acquires majority stake in NJ Bio, strengthens US presence
Suven Pharmaceuticals Limited, a technology-focused contract development and manufacturing organisation (CDMO), has announced the acquisition of a controlling 56% stake in NJ Bio Inc., a ... Read More
Innovent Biologics showcases promising preclinical data at AACR 2024
In a significant development for cancer research, Innovent Biologics, Inc. (HKEX: 01801), a leading biopharmaceutical company renowned for its innovative medicines in oncology, cardiovascular and ... Read More